Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Institut Bergonié
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Proportion of patients with pretreatment sarcopenia identified by analysis of the baseline CT-scan (CT0).
Study Overview
Brief Summary
Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.
Detailed Description
Prior to carrying out the research, the informed consent of the person must be obtained after being informed of the purpose of the research, its conduct and duration, benefits, potential risks and constraints of the study.
Before inclusion,all eligibility criteria will be verified.
Sarcopenia in patients with inoperable, high-grade epithelial ovarian carcinoma will be evaluated at different times:
- before treatment, in the 30 days prior to their inclusion in the study,
- after 3 neoadjuvant chemotherapy cycles,
- after 3 adjuvant chemotherapy cycles,
- 9 months after surgery. The reference detection method is by CT-scan. This will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.
On inclusion, the patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years.
- •Inoperable, high-grade, epithelial ovarian carcinoma requiring perioperative chemotherapy (neoadjuvant and adjuvant).
- •Optical medical treatment (carboplatin-taxol chemotherapy every 3 weeks) and surgery at Institut Bergonié.
- •Non-clinically undernourished patient, i.e. without loss of more than 10% bodyweight in 6 months
- •Free, informed and written consent signed by the participant and the investigator (on the day of inclusion at the latest and before any tests required for the research).
- •Patient with social security cover in accordance with Article 1121-11 of the French code of public health.
Exclusion Criteria
- •Contraindication to CT-scans.
- •Contraindication to bone mineral densitometry.
- •Patients over the age of 70 the G8 of whom requires oncogeriatric surgery.
- •Patients under guardianship, vulnerable patients or patients under any other legal protection measures.
- •Geographic, social or psychological factors meaning the patient is unable to commit to study follow-up and procedures.
- •Patient already included in this study or in another study evaluating the impact of sarcopenia.
Arms & Interventions
patients with inoperable high-grade ovarian carcinoma
Evaluation of sarcopenia in patients with inoperable high-grade ovarian carcinoma as part of optimised management
Intervention: Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA). (Other)
Outcomes
Primary Outcomes
Proportion of patients with pretreatment sarcopenia identified by analysis of the baseline CT-scan (CT0).
Time Frame: Baseline
Proportion of patients with pretreatment sarcopenia identified by analysis of the baseline CT-scan (CT0). According to the 2019 HAS guidelines \[Diagnosis of undernutrition in children and adults, November 2019\], we consider the patient to have sarcopenia if her MSI is strictly below 38.5 cm2/m2.
Secondary Outcomes
- The time of access to chemotherapy(From the date of surgery to the start date of adjuvant chemotherapy, assessed up to 2 months from surgery)